State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access to Novo Nordisk's Wegovy or Eli Lilly's Zepbound, according to the AXIACI ...

Bagsværd, Denmark, 8 November 2024 - Today, Novo Nordisk A/S has entered into an agreement to purchase 6,311,250 B shares of DKK 0.10 at a value of DKK 4,736,088,225.00 from Novo Holdings A/S. The ...

SINGAPORE - Media OutReach Newswire - 22 December 2023 - Novo Nordisk Pharma (Thailand) Ltd. has emerged triumphant by securing three prestigious accolades at the Asia Pacific Enterprise Awards (APEA) ...

Novo Nordisk (NVO) has released an update. Novo Nordisk has disclosed share transactions by its board members and executives, highlighting a significant purchase of 1,400 American Depositary ...

UBS analyst Jo Walton maintained a Hold rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK1,100.00. The company’s shares closed yesterday at DKK802.60.

(Bloomberg) -- Novo Nordisk A/S posted surging sales of its blockbuster weight-loss treatment Wegovy, reassuring investors after rival Eli Lilly & Co. reported disappointing sales of its obesity ...

even their letter O sometimes comes slashed in half. But, Denmark is also home to what is suddenly Europe's largest company—Novo Nordisk…. a pharmaceutical firm with a market cap of a half ...

LONDON, Nov 6 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 drugs already on the ...

Novo Nordisk, after mulling the implications of a phase 3 fail, has given up on a late-stage kidney drug acquired in a $1.3 billion deal. The Danish pharma bought the nonsteroidal ...

Novo Nordisk on Wednesday reported third quarter earnings broadly in line with expectations, said that its net profit in the third quarter hit 27.3 billion Danish kroner, just above an LSEG ...

“Honestly, I’m quite alarmed by what we see in the US now,” Novo Nordisk President and CEO Lars Fruergaard Jorgensen told CNN. “Patients who believe that they’re getting access to a safe ...